Heart Disease News and Research

Latest Heart Disease News and Research

Mount Sinai receives contract to develop nanotechnology tools for diagnosing diseases

Mount Sinai School of Medicine received a contract for almost $16.5 million from The National Institutes of Health (NIH) and the National Heart and Lung Institute (NHLBI) through the Program of Excellence in Nanotechnology (PEN). The contract is one of four issued nationally to develop multidisciplinary research Centers with the goal of developing nanotechnology tools for diagnosing and treating heart, lung and blood diseases.

30 Sep 2010

Washington University receives award to develop diagnostic tools for heart, lung diseases using nanotechnology

An $18 million research program headed by Washington University School of Medicine in St. Louis will research therapies and diagnostic tools for heart and lung diseases that use nanotechnology.

30 Sep 2010

Feeding infants before examination for retinopathy of prematurity reduces stress

Premature infants are often examined for retinopathy of prematurity (ROP). This exam can be quite stressful for the neonate, causing changes in heart rate, blood pressure and oxygen saturation, and increased crying. In a recent study published in the Journal of AAPOS, the Official Publication of the American Association of Pediatric Ophthalmology and Strabismus, researchers found that feeding infants one hour before the examination unexpectedly reduced stress but did not increase vomiting or gastric aspirates.

30 Sep 2010

ThromboGenics enters 10-year supply agreement with MSD Biologics for microplasmin

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that it has signed a 10-year supply agreement with MSD Biologics (UK) Ltd, part of the Merck BioManufacturing Network, for the production of microplasmin. ThromboGenics anticipates that this deal will meet its long-term commercial needs for bulk drug substance of this novel therapeutic agent.

30 Sep 2010

UTHealth researcher receives grant to develop biochemical diagnosis test for Alzheimer's disease

The Alzheimer's Association has awarded a three-year, $200,000 grant to Claudio Soto, Ph.D., professor of neurology at The University of Texas Health Science Center at Houston (UTHealth), to pursue a procedure that could detect pre-symptomatic Alzheimer's disease.

30 Sep 2010

Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study

Results from a randomized, double-blinded, placebo-controlled, multicentred study just published in the Journal of Drugs in Dermatology shows that treating Actinic Keratoses (AK) with imiquimod 3.75% (Zyclara®) following cryotherapy was more effective than cryotherapy alone in reducing total AK lesion count and achieving complete clearance of AK.

30 Sep 2010

Study indicates garlic could help prevent cardiomyopathy

Garlic has significant potential for preventing cardiomyopathy, a form of heart disease that is a leading cause of death in people with diabetes, scientists have concluded in a new study. Their report, which also explains why people with diabetes are at high risk for diabetic cardiomyopathy, appears in ACS' bi-weekly Journal of Agricultural and Food Chemistry.

30 Sep 2010

Obama challenged on health care in Iowa meeting

The Washington Post: "Back in Iowa, President Obama got an earful Wednesday from voters about two of his key policies: health care, and his desire to roll back Bush-era tax cuts. ... Standing in the back yard of a resident, Obama stood patiently as one woman described, at length, her fears that the U.S. health-care system will soon resemble that of Great Britain. ... The official topic in Iowa was 'challenges currently facing the middle class,' part of a series of similar economy-driven stops" (Kornblut, 9/29).

30 Sep 2010

ACT updates myoblast program for heart failure treatment

Advanced Cell Technology, a leader in the field of regenerative medicine, provided an update today on the status of its myoblast program. The program has successfully and safely completed Phase I human clinical trials in more than forty patients in over four independent studies.

30 Sep 2010

USFDA grants Sun Pharma subsidiary tentative approval for generic Crestor ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of IPR Pharmaceutical's Crestor ® tablets 5 mg, 10 mg, 20 mg, 40 mg.

30 Sep 2010

Study shows blueberries may help fight atherosclerosis

Blueberries may help fight atherosclerosis, also known as hardening of the arteries, according to results of a preliminary U.S. Department of Agriculture funded study with laboratory mice. The research provides the first direct evidence that blueberries can help prevent harmful plaques or lesions, symptomatic of atherosclerosis, from increasing in size in arteries.

30 Sep 2010

Precautionary guidelines on flu vaccine safety for allergic children

With the flu season looming and health officials calling for across-the-board immunization, some parents may wonder just how safe the egg-based flu vaccine is for children with allergies. Pretty safe, say pediatricians from Johns Hopkins Children's Center: Even though the flu vaccine contains egg protein, most children with egg and other food allergies can be immunized safely with a few basic precautions.

30 Sep 2010

NEUROKIN accentuates its leadership in the treatment of acute neurological diseases

Bbiotechnology company NEUROKIN, dedicated to the development of neuroprotective drugs to treat acute neurological diseases, announces today that the European Patent Office (EPO) has granted patent EP 1998778 protecting the use of NK-102, its most advanced drug candidate. This first European award constitutes an important milestone for NEUROKIN. An application for registration is under way in Brazil, Canada, China, USA and Japan.

29 Sep 2010

Social rejection can ‘brake’ your heart

Latest study shows that a social rejection can not only break a person’s heart but also result in a drop in the heart rate. The researchers from Netherlands found that the disappointment of feeling not loved or not liked can cause both psychological and physical reactions.

29 Sep 2010

IN.PACT drug-eluting balloons show promising results for superficial femoral artery disease treatment

Advancing research on drug-eluting balloons for the treatment of coronary and peripheral artery disease, Medtronic, Inc., today announced the latest results from the IN.PACT drug-eluting balloon (DEB) clinical program presented last week at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference.

29 Sep 2010

AccessClosure enters agreement with Benrikal Services for Bengal Radial Compression Band distribution

AccessClosure, Inc., the market leader in extravascular closure devices, announced today an exclusive agreement with Benrikal Services to distribute the Bengal Radial Compression Band in the United States.

29 Sep 2010

Pulmokine receives NIH SBIR grants to develop novel treatments for PAH

YM BioSciences Inc., today reported that Pulmokine Inc. (Slingerlands, New York), a licensee of several small molecule compounds from YM, has been awarded two National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grants. The grants, totaling more than US$650,000, are Phase I awards to develop novel treatments for Pulmonary Arterial Hypertension (PAH).

29 Sep 2010

New program offers options for fertility preservation in children with cancer

It is estimated that 1 in 500 children will be diagnosed with a form of childhood cancer. Fortunately, with the use of aggressive treatment modalities, more than 75% of these children will be cured. Therefore, many of these children and parents are looking beyond the cancer at important quality of life issues and guiding their treatments to assure "normal" post-cancer survivorship.

29 Sep 2010

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes.

29 Sep 2010

Predisposition of individuals from various ethnic groups to heart disease in later life: Study

Researchers at the University of Hertfordshire will carry our research into the predisposition of individuals from various ethnic groups to heart disease in later life when it carries out screening this week.

29 Sep 2010

Heart Disease News and Research

Latest Heart Disease News and Research

Mount Sinai receives contract to develop nanotechnology tools for diagnosing diseases

Washington University receives award to develop diagnostic tools for heart, lung diseases using nanotechnology

Feeding infants before examination for retinopathy of prematurity reduces stress

ThromboGenics enters 10-year supply agreement with MSD Biologics for microplasmin

UTHealth researcher receives grant to develop biochemical diagnosis test for Alzheimer's disease

Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study

Study indicates garlic could help prevent cardiomyopathy

Obama challenged on health care in Iowa meeting

ACT updates myoblast program for heart failure treatment

USFDA grants Sun Pharma subsidiary tentative approval for generic Crestor ANDA

Study shows blueberries may help fight atherosclerosis

Precautionary guidelines on flu vaccine safety for allergic children

NEUROKIN accentuates its leadership in the treatment of acute neurological diseases

Social rejection can ‘brake’ your heart

IN.PACT drug-eluting balloons show promising results for superficial femoral artery disease treatment

AccessClosure enters agreement with Benrikal Services for Bengal Radial Compression Band distribution

Pulmokine receives NIH SBIR grants to develop novel treatments for PAH

New program offers options for fertility preservation in children with cancer

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

Predisposition of individuals from various ethnic groups to heart disease in later life: Study

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Heart Disease News and Research

Latest Heart Disease News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in